Lv62
2250 积分 2023-02-21 加入
Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio
6天前
已完结
First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds
12天前
已完结
Method comparison and re-calibration of three top-used immunoassays and one LC-MS/MS assay for four core cerebrospinal fluid biomarkers of Alzheimer’s disease: an explorative study for harmonization
25天前
已完结
Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer’s disease
25天前
已完结
Method comparison and re-calibration of three top-used immunoassays and one LC-MS/MS assay for four core cerebrospinal fluid biomarkers of Alzheimer’s disease: an explorative study for harmonization
25天前
已完结
Prospective study on clinical utility of plasma p-Tau217 and other biomarkers in Japanese memory clinics using the LUMIPULSE platform
1个月前
已完结
Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer’s disease using the Lumipulse platform
1个月前
已完结
A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies
2个月前
已完结
A biomarker of Alzheimer’s disease could be a useful diagnostic tool for other amyloidoses
3个月前
已完结
Real-life reliability of plasma pTau181, Aβ42/Aβ40, and pTau181/Aβ42 measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid status
3个月前
已完结
皖公网安备34019202002308
